<DOC>
	<DOCNO>NCT01206010</DOCNO>
	<brief_summary>Varenicline partial nicotinic agonist act alpha4 beta2 nicotinic receptor . It presume alleviate withdrawal discomfort , also diminish reward effect cigarette . The standard varenicline dosing formulate avoid adverse reaction ( primarily nausea ) sensitive client . The downside cautious approach substantial proportion client may under-dosed . A blanket dose increase would inevitably increase incidence side effect , likely tailor varenicline dose client ' need would safe may increase varenicline 's efficacy . This study recruit 200 smoker report little change enjoyment cigarette nausea , first week varenicline use . These smoker randomise receive standard dose plus placebo plus individualised varenicline dose 5mg , titrate next week prior target quit day . Urges smoke , withdrawal symptom , experience study period compare group see tailored therapy may useful .</brief_summary>
	<brief_title>Tailoring Varenicline Individual Needs ( TVIN Study )</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Smoker seek treatment Aged 18 Consenting take part Report little change enjoyment cigarettes and/or nausea Pregnant breastfeeding Have severe kidney disease Have severe heart problem Have current psychiatric illness Are unable fill questionnaire English Have allergy varenicline Are currently involve another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Tobacco Dependence</keyword>
	<keyword>Smoking cessation</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Tailored dosing</keyword>
</DOC>